VERU Inc.
Veru is an oncology biopharmaceutical company developing: Enobosarm, a selective AR targeting agonist, in Phase 3 ARTEST study for 3rd line and in Phase 3 ENABLAR-2 study (enobosarm+abemaciclib) for 2nd line metastatic breast cancer (MBC); Sabizabulin, oral cytoskeleton disruptor, in Phase 2b for 3rd line ER+ MBC and in Phase 3 VERACITY study for metastatic castration resistant prostate cancer; VERU-100, a long-acting GnRH antagonist, in Phase 2 study for androgen deprivation therapy (ADT); and Zuclomiphene, oral nonsteroidal ER agonist, in planned Phase 2 for hot flashes caused by ADT.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No